Plasma concentration of 5-fluorouracil predicts the efficacy and safety of capecitabine plus cisplatin as first-line chemotherapy in patients with advanced gastric cancer: A single-center clinical trial
10.3781/j.issn.1000-7431.2013.09.008
- Author:
Wei-Feng SONG
1
Author Information
1. Department of Medical Oncology
- Publication Type:Journal Article
- Keywords:
Capecitabine;
Fluorouracil;
Plasma drug concentration;
Stomach neoplasms
- From:
Tumor
2013;33(9):795-801
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To assess the value of plasma concentration of 5-FU (5-fluorouracil) predicting the efficacy and safety in patients with advanced gastric cancer receiving capecitabine plus cisplatin as first-line chemotherapy. Methods: The clinical data from 113 advanced gastric cancer patients receiving capecitabine plus cisplatin in Shanghai First People's Hospital from July 2007 to December 2010 were retrospectively collected. The plasma concentration of 5-FU was examined at each cycle of chemotherapy. The relationships between plasma concentration of 5-FU and the OS (overall survival), PFS (progression-free survival) and RR (response rate) were determined by statistical analysis. Results: The mean plasma concentration of 5-FU was 25.8 μg/L. The patients were divided into group A (plasma concentration of 5-FU > 25 μg/L, n = 59) and group B (plasma concentration of 5-FU < 25 μg/L, n = 54). The median OS time of group A and group B were 14.4 and 9.6 months, respectively (hazard ratio = 0.36, P = 0.000). The median PFS time of group A and group B were 8.0 and 4.9 months, respectively (hazard ratio = 0.37, P = 0.000). The RR of group A and group B were 55.9% and 33.3%, respectively (P = 0.023). All toxicities occurred more frequently in group A than in group B. The grade III/IV mocositis and hand-foot syndrome were significantly increased in group A as compared with group B. Conclusion: For advanced gastric cancer, high plasma concentration of 5-FU might predict efficacy and toxicities of capecitabine plus cisplatin. Copyright © 2013 by TUMOR.
